ArticleTherapeutic advances in gastroenterology2026
Prognostic value of magnetic resonance imaging in pediatric-onset primary sclerosing cholangitis.
Article in Therapeutic advances in gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prognostic value of magnetic resonance imaging (MRI) in pediatric-onset primary sclerosing cholangitis (PSC) remains poorly studied. The MRI-based ANALI scores with and without gadolinium (ANALI Objectives: To assess the prognostic relevance of ANALI scores in pediatric-onset PSC. Design: This retrospective cohort study was conducted at a single tertiary-care center and included patients with pediatric-onset PSC identified from a national PSC registry. Methods: We included 34 patients with pediatric-onset PSC (median age at diagnosis 14 years, interquartile range (IQR) 12.0-16.3; median follow-up time 10.4 years, IQR 7.0-13.2) who had undergone at least two MRIs. Two expert radiologists evaluated the presence of intrahepatic duct dilatation, hepatic dysmorphia, collateral veins, and parenchymal enhancement heterogeneity, which were used to calculate ANALI scores for the baseline and follow-up MRIs. The longitudinal development of ANALI scores was assessed, and the association between scores and clinical endpoints (decompensated cirrhosis, liver transplantation) was examined using Cox proportional hazards regression. Interrater agreement was evaluated for the total scores and the individual score items. Results: Disease progression was variable, and baseline ANALI scores alone did not predict adverse outcomes. When follow-up scores were also assessed, higher scores were associated with outcomes (hazard ratio (HR) per 1-point increase in ANALI Conclusion: ANALI scores were associated with adverse outcomes in pediatric-onset PSC when assessed repeatedly during follow-up; baseline measurements alone may have limited prognostic value in the pediatric population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.